Trial · NCT03415152
Results by group51
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 51
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Adherence Rate at the End of the Study (Visit 3) | Omacor (Omega-3-acid Ethyl Esters) | 0.37 | Standard Deviation 0.38 | proportion of days | |
| Mean Score of National Questionnaire of Treatment Compliance (Edited by Fofanova T.V. et al.) at the End of the Study (Visit 3) | Omacor (Omega-3-acid Ethyl Esters) | 12.9 | Standard Deviation 2.99 | score on a scale | |
| The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination | Omacor (Omega-3-acid Ethyl Esters) | Adverse drug reactions | 0 | percentage of participants | |
| The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination | Omacor (Omega-3-acid Ethyl Esters) | Lack of efficacy | 0.08 | percentage of participants | |
| The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination | Omacor (Omega-3-acid Ethyl Esters) | Inconvenience of use | 0.43 | percentage of participants | |
| The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination | Omacor (Omega-3-acid Ethyl Esters) | Absence at the pharmacy | 0.23 | percentage of participants | |
| The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination | Omacor (Omega-3-acid Ethyl Esters) | Other reason | 1.94 | percentage of participants | |
| The Percentage of Patients Who Have Chosen Each of the Suggested Reasons for Therapy Termination | Omacor (Omega-3-acid Ethyl Esters) | Total | 2.68 | percentage of participants | |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Physical functioning (V2-V1,3 m) | 7.63 | Standard Deviation 13.4 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Role limitations due to physical health (V2-V1,3m) | 32.86 | Standard Deviation 48.42 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Role limitations due to emotional problems (V2-V1, | 25.71 | Standard Deviation 32.42 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Energy/fatique (V2-V1,3m) | 20.81 | Standard Deviation 14.12 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Emotional wellbeing (V2-V1,3m) | 22.66 | Standard Deviation 14.69 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Social functioning (V2-V1,3m) | 26.43 | Standard Deviation 25.68 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Pain (V2-V1,3m) | 8.43 | Standard Deviation 14.12 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | General health (V2-V1,3m) | -6.14 | Standard Deviation 10.22 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Physical functioning (V3-V1,6m) | 6.69 | Standard Deviation 10.08 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Role limitations due to physical health (V3-V1,6m) | 29.55 | Standard Deviation 43.39 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Role limitations due to emotional problems (V3-V1, | 18.18 | Standard Deviation 30.39 | score on a scale |
| The Average Score on Each of 8 Scales of Short Form Survey (SF)-36 Quality of Life Questionnaire at Visit 2 and Visit 3 vs. the Baseline (Visit 1) | Omacor (Omega-3-acid Ethyl Esters) | Energy/fatique (V3-V1,6m) | 18.18 | Standard Deviation 13.59 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03415152/results